A Ad Add dr dress for r Co Co Corr rr rres spo po pond nd nden n ence ce e: : : Jo o Josh h hua u A. Be eckma ma man, M M MD D D, M M MS S S Ca Card rd rdio io iova va vasc sc scul ul u ar ar D D Div iv vis is si io ion n n B Bri igh ham and d Wo Wome men' n's s Ho Hosp sp pit ital al 75 F i S 2 The cardiovascular management of the patient undergoing non-cardiac surgery has been in evolution for the last 35 years. Over this time frame, two secular trends have advanced in parallel but provided contrary practice implications for the care of the surgical patient. First, cardiovascular event rates have been dropping significantly over time. In 1977, Goldman and colleagues created a risk evaluation system that predicted a 22% rate of "life-threatening" cardiovascular events and more than 50% mortality in the highest risk group 1 in 1001 patients undergoing surgery. These rates of events have dropped each decade since significantly. Finks and colleagues reported 2 years ago a mere 2.8% national mortality rate for open abdominal aortic aneurysm repair; the exemplar of routine, high-risk surgery 2 . These numbers were recapitulated world-wide for high-risk patients undergoing noncardiac surgery in the PeriOperative ISchemic Evaluation (POISE) trial 3 . Improvements in surgical and anesthetic techniques, perioperative medical therapy, and intensive care have each participated in the significant improvement in outcomes.
in the stable patient by diminishing the risk of the group with a "positive study." Second, everdropping event rates largely render the prognostic value of these tests moot. A three-fold hazard ratio in the setting of a 1-3% surgical mortality provides little insight into patient selection for higher level therapies beyond medical therapy. Because of the overall low mortality and the limited value of noninvasive testing to clarify outcome and need for preoperative coronary artery revascularization 5 , there has been an increase in effort to find patients at heightened risk postoperatively to stave off severe adverse events. Over the last decade, much of this effort has focused on biomarkers of myocardial injury, the cardiac troponins.
The troponin complex is co-located with tropomyosin on the actin filament and participates in cardiac muscle contraction. The complex consists of three peptide components, T, I, and C. The first two have been used in the measurement of myocardial injury whereas troponin C, the calcium binding site, is not because of its shared location in skeletal muscle. Measurement of troponin T was approved by the Food and Drug Administration in 1996 and its uptake into the medical practice was rapid. Just 4 years later, the cardiology community made troponin the preferred biomarker to diagnose myocardial infarction 6 as part of the guideline process. By 2007, troponin measurement became the de facto global standard when the first Universal Definition of Myocardial Infarction was published 7 . Over the last decade, the troponin use has skyrocketed beyond the limited use for determining the presence or absence of an acute coronary syndrome and become a nonspecific marker of illness. Indeed, the value of troponin in the diagnosis of myocardial infarction may have reached its apex in 2001 with the publication of the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) study. The investigators showed that early invasive therapy was superior to a conservative approach in patients presenting to the hospital with chest pain with a troponin T of participates in cardiac muscle contraction. The complex consists of three peptid de e co o omp mp pon n onen en ents ts t , , T, , and C. The first two have been used in the measurement of myocardial injury whereas troponin Subsequently, troponin has been measured in a wide variety of settings to provide prognostic information in diseases that do not originate in the coronary arteries. Prognostic information has been generated for diseases that originate with the heart, affect the heart, are remote from the heart, and have extended to patients who aren't acutely ill. Elevations in troponin associate with worse outcomes in patients with myocarditis 9 , congestive heart failure 10, 11 , and cardiac contusions 12 showing the value of this biomarker in a broad range of cardiac disease. Troponin release provides significant prognostic information for pulmonary disease, presumably because of its direct vascular coupling with the right ventricle. For example, many studies have shown that troponin release during pulmonary embolism is a marker of severity and adverse prognosis [13] [14] [15] . Similarly, elevations in troponin during chronic obstructive pulmonary disease exacerbation are associated with a greater need for ventilator support and worse longterm survival 16 . The release of troponin is thought to result from a direct increase in right ventricular overload and right heart strain.
Perhaps more impressively, release of cardiac troponin has become sensitive enough to act a barometer of the severity of illness unrelated to the heart. Patients with septicemia who have measurable troponin levels suffer worse outcomes than those who do not, even after adjustment for other prognostic markers 17 . Similarly, the release of troponin predicts poorer outcomes in patients admitted with subarachnoid hemorrhage [18] [19] [20] . More recently, investigators have shown that troponin release may occur in the absence of overt illness and provide prognostic data for outcomes in the non-hospitalized person. Using a high-sensitivity troponin T disease. Troponin release provides significant prognostic information for pulmon n nary ry y d d dis is isea ea ease se se, ,
presumably because of its direct vascular coupling with the right ventricle. For example, many Second, what are the probability and potential adverse consequences of a false positive result?
For this, I would refer to the vanishingly small number of type 1 myocardial infarctions diagnosed and worry that management for plaque rupture events (antiplatelet therapy, anticoagulation, and possibly catheterization) would be provided for patients with hemodynamic (type 2 myocardial infarction) events. None of these interventions is likely beneficial for the vast majority of patients, particularly early after major surgery when the troponin is likely to be elevated. As noted by Van Waes and the VISION investigators, the majority of troponin T release occurs by the end of post-operative day 1, a high-risk period for bleeding. Third, is the patient in potential danger over the short term if I do not perform this test? Although it is certainly true that an elevation in troponin portends adverse outcome, the lack of specificity concerning the mechanism of adverse outcome suggests that the test will not foster a change or modification of therapy. In a small study of patients over aged 60 years undergoing emergency orthopedic surgery, the addition of cardiovascular care to troponin positive patients did not affect in-hospital cardiovascular complications or 1 year mortality 27 . Most telling, however, is that the cardiologists did little to alter care. No coronary angiography was performed and only 1 in 6 patients seen by cardiologists had the addition of aspirin, beta blockers, or both.
It is the author's opinion that improvements in troponin T assay sensitivity have created a condition in which the biomarker is so easily measured that it now culls out patients at higher risk for any adverse event more than diagnoses cardiac-specific events. Indeed, one may suggest that the results are similar to the Dallas Heart Study, but instead of free-living individuals, the perioperative patient population represents an asymptomatic group exposed to surgical stress, 27 27 27 . . Mo Mo Most st st t t tel el elli li ing ng ng, , ho ho howe we weve ve ver, r is that the e e absence of any demonstrated beneficial treatment strategy, the possibility of harm in applying the standard treatment for type 1 myocardial infarction, and the potential to divert attention from a true cause of adverse event (non-vascular morbidity) to a false one (myocardial infarction), the author believes that routine measurement of troponin is more likely to cause harm than provide benefit and should not be used as a screening modality.
Currently, low rates of overall perioperative mortality in the setting of guidelines based care 28 have made risk prediction difficult and largely limited the task of risk assessment to ferreting out patients with active cardiac conditions, severe pulmonary disease, or severe underlying medical illness. These factors may or may not be related to the features seemingly most predictive of troponin release, such as intra-operative hypotension, pre-operative hypertension, and the presence of atherosclerosis [29] [30] [31] . Studies are ongoing to determine response strategies to elevations of troponin post-operatively, but until a specific strategy or treatment is identified, the ontogeny of troponin testing makes unlikely patient benefit from its routine measurement after noncardiac surgery.
